You are here

Article Text

Article menu
Download PDFPDF
Letter
Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer
  1. Antoine Adenis1,
  2. Luc Vanseymortier1,
  3. David Foissey1,
  4. Jean-Frédéric Colombel2
  1. 1Department of Gastrointestinal Oncology, Centre Oscar Lambret, Lille, France
  2. 2Department of Gastroenterology, Hôpital Huriez, Lille, France
  1. Correspondence to:
    Professor A Adenis
    Department of Gastrointestinal Oncology, Centre Oscar Lambret, 3 rue Combemale, 59020 Lille, France; a-adenis{at}o-lambret.fr

http://dx.doi.org/10.1136/gut.2006.112524

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Bevacizumab is a murine-anti-human monoclonal antibody directed against vascular endothelial growth factor-A, which disrupts endothelial cell survival mechanisms, and the recruitment and development of new tumour blood supply. Bevacizumab has been shown to prolong the duration of survival of patients with metastatic colorectal cancer when combined with chemotherapy.1 Owing to its antiangiogenic properties, bevacizumab is also known to alter the healing process and to increase the rate of surgical wound healing complications, either in patients who underwent …

    View Full Text

    Footnotes

    • Competing interests: None.